Exscientia plc (NASDAQ:EXAI) Sees Significant Decline in Short Interest

Exscientia plc (NASDAQ:EXAI) was the target of a significant decrease in short interest in September. As of September 30th, there was short interest totalling 2,890,000 shares, a decrease of 9.7% from the September 15th total of 3,200,000 shares. Currently, 2.7% of the company’s stock are sold short. Based on an average daily volume of 676,600 shares, the short-interest ratio is currently 4.3 days.

Wall Street Analysts Forecast Growth

EXAI has been the subject of several recent analyst reports. TD Cowen reissued a “hold” rating on shares of Exscientia in a report on Friday, August 9th. Barclays reiterated an “equal weight” rating and issued a $5.00 target price on shares of Exscientia in a research note on Tuesday, August 13th.

Exscientia Stock Performance

Exscientia stock traded down $0.23 during trading hours on Thursday, hitting $5.06. 577,434 shares of the stock traded hands, compared to its average volume of 644,563. The firm’s 50 day moving average price is $5.14 and its 200-day moving average price is $5.06. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.93 and a quick ratio of 5.93. The stock has a market capitalization of $611.69 million, a price-to-earnings ratio of -3.86 and a beta of 0.84. Exscientia has a 1 year low of $3.80 and a 1 year high of $7.91.

Exscientia (NASDAQ:EXAI) last issued its earnings results on Thursday, August 15th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.05). The firm had revenue of $5.60 million during the quarter. Exscientia had a negative net margin of 620.99% and a negative return on equity of 37.56%. As a group, equities analysts expect that Exscientia will post -1.25 EPS for the current fiscal year.

Institutional Trading of Exscientia

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Novo Holdings A S purchased a new stake in Exscientia in the 2nd quarter worth approximately $66,742,000. Bank of New York Mellon Corp lifted its stake in shares of Exscientia by 108.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 388,459 shares of the company’s stock valued at $1,981,000 after purchasing an additional 202,377 shares during the period. Susquehanna Fundamental Investments LLC acquired a new position in shares of Exscientia in the 2nd quarter valued at $256,000. Federated Hermes Inc. purchased a new stake in Exscientia during the second quarter worth $115,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in Exscientia during the second quarter valued at $54,000. 41.58% of the stock is owned by institutional investors and hedge funds.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.